3’-Deoxy-3’-[18f]-fluorothymidine PET/CT in Early Determination of Prognosis in Patients with Esophageal Squamous Cell Cancer
Haojun Chen,Yimin Li,Hua Wu,Long Sun,Qin Lin,Long Zhao,Hanxiang An
DOI: https://doi.org/10.1007/s00066-014-0744-8
2014-01-01
Strahlentherapie und Onkologie
Abstract:Purpose The purpose of this work was to investigate the prognostic value of response analysis using early 3'-deoxy-3'-[F-18]-fluorothymidine (F-18-FLT) PET/CT in esophageal squamous cancer patients and make a comparison with [F-18]-fluorodeoxyglucose (F-18-FDG) PET/CT.Patients and materials For 34 patients with esophageal squamous cell cancer, both F-18-FLT PET/CT and F-18-FDG PET/CT scans were performed at baseline (pre), 4 weeks after the start of radiotherapy or chemoradiotherapy (interim), and 2 weeks after therapy completion (final). SUV(max)1, SUV(max)2, and SUV(max)3 represent SUVmax (SUV: standard uptake values) measured on the pre, interim, and final scans, respectively. GTV(FLT-PET) and GTV(FDG-PET) (GTV: gross tumor volume) were measured on the pre and interim scans. Delta SUV/Delta GTV represents the fractional changes of SUVmax/GTV between two different time points. PET parameters were evaluated for correlations with outcome.Results Regarding F-18-FLT PET/CT, according to receiver operating characteristic (ROC) curve analysis, parameters for predicting 2-year progression-free survival (PFS) and locoregional control (LRC) showed the highest area under curve (AUC) on interim F-18-FLT PET/CT scans (Delta SUV12, AUC of 0.812 for PFS, 0.775 for LRC, with a cutoff of 60 %; P = 0.008), compared with the parameters on pre and final scans. Patients with a Delta SUV12 greater than 60 %, who were defined as interim PET-negative group, were associated with better 2-year PFS and LRC than the interim PET-positive group (PFS: 70.6 % vs. 35.2 %, P = 0.025; LRC: 84.2 % vs 52.9, P = 0.046). In terms of F-18-FDG PET/CT, Delta SUV13 on the final 18F-FDG PET/CT scan demonstrated better prediction (AUC of 0.812 for PFS, 0.807 for LRC, with a cutoff of 75 %; P = 0.016) than the parameters on pre and interim scans. An SUVmax decrease >= 75 % on the final F-18-FDG PET/CT scan was associated with better clinical outcome (PFS: 73.3 % vs. 36.8 %, P = 0.022; LRC: 86.7 % vs 52.6, P = 0.029). These correlations were most prominent in the subgroup of patients treated with chemoradiotherapy.Conclusion Early interim F-18-FLT PET/CT is a significant predictor of 2-year PFS and LRC, which is correlated better with early responses and late outcomes than interim F-18-FDG PET/CT in esophageal squamous cancer patients.